Business
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf,
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference.\n\n\nOppenheimer 33rd Annual Virtual Healthcare Conference being held March 13 – 15, 2023. Presentation time Tuesday, March 14, from 9:20 – 9:50 AM ET.\n\n\nTo participate in the audio webcast, interested parties can access the live webcast under \"News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.\n\nAbout Aurinia\n\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by autoimmune, kidney and rare diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230224005026/en/\n\nInvestor/Media Contact:\[email protected]\n\nSource: Aurinia Pharmaceuticals Inc.","length":2774,"tagName":"div"}]